Clinical trials: Tetanus-diphtheria-acellular Pertussis (Tdap)
- Condition Tetanus-diphtheria-acellular Pertussis (Tdap)
- Funder type Industry (pharma, biotech, devices)
Healthy Subjects
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group 1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP), Group 2: 7-valent…
- Trial name
- NCT01200368
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), 7-valent pneumococcal conjugate vaccine (7vPnC)
- Where
- 32 sites in Japan
- Volunteers
- 551 people
- Sponsor
- Pfizer
Pertussis, Tetanus
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
This study is designed to assess the immunogenicity and safety of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (ADACEL®, Tdap vaccine) as a booster dose in adolescents in Japan.
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT01689324
- Testing
- (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis
- Where
- 3 sites in Japan
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
The purpose of this study is to generate immunogenicity and safety data of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine compared to a control vaccine, Infanrix hexa™ when given along with Prevenar™ and Rotarix™…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01177722
- Testing
- DTaP-IPV-Hep B-PRP-T Vaccine, DTaP-Hep B-IPV vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus, Acellular Pertussis
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults
The purpose of this follow-up study is to evaluate the persistence of antibodies against all the vaccine antigens 10 years after booster vaccination with either Tdap or Td, and also to assess immunogenicity and safety of another…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT01738477
- Testing
- Boostrix
- Where
- 20 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
The purpose of this study is to evaluate the persistence of antibodies against all the vaccine antigens 1, 3, 5 and 9 years after an initial vaccination with Tdap, and also to assess immunogenicity and safety of another dose of…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00489970
- Testing
- Taking of blood samples, Boostrix, Adacel
- Where
- 37 sites in United States
- Volunteers
- 1,954 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Acellular Pertussis
Duration of Protection: GSK DTaP Vaccines
The purpose of this study is to assess duration of protection for GSK DTaP vaccines in preventing pertussis.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT02447978
- Testing
- Infanrix, Pediarix, Kinrix
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design.
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
- Trial name
- NCT07203755
- Testing
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Diphtheria, Acellular Pertussis
Post Market Surveillance for Infanrix™
The purpose of this study was to investigate the following questions through post-marketing surveillance: Unknown/Unexpected adverse events and the serious adverse events.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00908115
- Testing
- GSK Biologicals' Infanrix™
- Where
- South Korea
- Volunteers
- 1,258 people
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Diphtheria
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.
The aims of this study are to evaluate the safety and immunogenicity of a booster dose of GSK Biological's candidate Tdap vaccine containing 0.3 mg Al when administered to healthy school children and adolescents (9-13 years of…
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00263679
- Testing
- Prophylaxis: Diphtheria, tetanus and pertussis
- Where
- 13 sites in Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcemia
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
The purpose of this study was to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and Tdap vaccine in adolescents aged 11 to 17 years.
- Conditions
- Meningitis, Meningococcemia, Pertussis, Tetanus
- Trial name
- NCT00777257
- Testing
- T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
- Where
- 20 sites in United States
- Volunteers
- 1,345 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meningitis
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by…
- Trial name
- NCT01424644
- Testing
- MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Where
- 20 sites in United States, Italy
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Novartis
Acellular Pertussis, Diphtheria
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00346073
- Testing
- Boostrix™, ADACEL®
- Where
- 42 sites in United States
- Volunteers
- 2,337 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Tetanus
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.
- Conditions
- Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00319553
- Testing
- ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
- Where
- 10 sites in United States
- Volunteers
- 647 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pertussis
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
The purpose of this study is to evaluate the persistence of immune response against the three pertussis antigens (anti- pertussis toxoid (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN)) in subjects who…
- Trial name
- NCT02382913
- Testing
- aP booster, TdaP booster, Licensed TdaP booster (Boostrix®)
- Where
- Belgium
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy Volunteers
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants.
- Trial name
- NCT06344065
- Testing
- Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed), Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine
- Where
- China
- Volunteers
- 1,584 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Tetanus, Acellular Pertussis
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00148941
- Testing
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3
- Where
- 24 sites in United States
- Volunteers
- 4,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents
This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as follows: To confirm the non-inferiority of BK1301 to Adsorbed…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT02118961
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301), Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)
- Where
- 7 sites in Japan
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers)
A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada
The primary objectives of this study are: To describe the safety profile of each of the investigational vaccine formulations for all participants To describe the humoral and cell-mediated immune responses to all of the…
- Conditions
- Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)
- Trial name
- NCT03958799
- Testing
- Investigational Tdap vaccine Formulation B, Investigational Tdap vaccine Formulation C, Investigational Tdap vaccine Formulation A
- Where
- 5 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Acellular Pertussis
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00263692
- Testing
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Where
- 15 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline